PGNY - NASDAQ
Progyny, Inc.
$24.99
-4.6%Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
At a Glance
Live SnapshotProgyny, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Efficient profit conversion: Minimal margin compression from gross to net indicates lean operations and favorable tax/interest environment.
Progyny, Inc. Income Statement
PGNY • NASDAQ
| Progyny, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
1.3B | 1.2B | 1.1B | 786.9M | 500.6M | 344.9M | 229.7M | 105.4M | 48.6M | |
GROSS PROFIT | |||||||||
(984.2M) | (913.9M) | (849.8M) | (619.6M) | (388.5M) | (274.8M) | (184.2M) | (86M) | (41.2M) | |
304.5M | 253.4M | 238.8M | 167.3M | 112.1M | 70.1M | 45.5M | 19.4M | 7.4M | |
OPERATING INCOME | |||||||||
(219.2M) | (185.9M) | (176.6M) | (144M) | (79.8M) | (61.7M) | (35.8M) | (22.9M) | (18.4M) | |
(219.2M) | (185.9M) | (176.6M) | (144M) | (79.8M) | (61.7M) | (35.8M) | (22.9M) | (18.4M) | |
85.3M | 67.5M | 62.2M | 23.3M | 32.3M | 8.3M | 9.7M | -3.5M | -11M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (58K) | (497K) | (740K) | |
0.0 | 15.7M | 8.5M | 814K | 461K | 121K | -58K | -497K | -740K | |
10.2M | 15.7M | 8.5M | 1.1M | 95K | 331K | -18.2M | -3.4M | -1.5M | |
95.4M | 83.2M | 70.7M | 24.4M | 32.4M | 8.7M | -8.6M | -6.9M | -12.5M | |
NET INCOME | |||||||||
(36.9M) | (28.9M) | (8.7M) | -5.9M | -33.3M | -37.8M | (12K) | -1.8M | -3K | |
58.5M | 54.3M | 62M | 30.4M | 65.8M | 46.5M | -8.6M | 661K | -12.5M |
SEC Filings
PGNY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 13, 2026 | January 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 12, 2025 | 2025 |
Related Guides
Continue your PGNY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.